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Developmental fate decisions are dictated by master
transcription factors (TFs) that interact with cis-regu-
latory elements to direct transcriptional programs.
Certainmalignant tumorsmayalso dependon cellular
hierarchies reminiscent of normal development but
superimposed on underlying genetic aberrations. In
glioblastoma (GBM), a subset of stem-like tumor-
propagating cells (TPCs) appears to drive tumor pro-
gression and underlie therapeutic resistance yet
remain poorly understood. Here, we identify a core
set of neurodevelopmental TFs (POU3F2, SOX2,
SALL2, and OLIG2) essential for GBM propagation.
These TFs coordinately bind and activate TPC-spe-
cific regulatory elements and are sufficient to fully
reprogram differentiated GBM cells to ‘‘induced’’
TPCs, recapitulating the epigenetic landscape and
phenotype of native TPCs. We reconstruct a network
model that highlights critical interactions and iden-
tifies candidate therapeutic targets for eliminating
TPCs. Our study establishes the epigenetic basis of
a developmental hierarchy in GBM, provides detailed
insight into underlying gene regulatory programs, and
suggests attendant therapeutic strategies.
INTRODUCTION
In mammalian development, stem and progenitor cells differen-
tiate hierarchically to give rise to germ layers, lineages, and580 Cell 157, 580–594, April 24, 2014 ª2014 Elsevier Inc.specialized cell types. These cell fate decisions are dictated
and sustained by master regulator transcription factors (TFs),
chromatin regulators, and associated cellular networks. It is
now well established that developmental decisions can be
overridden by artificial induction of combinations of ‘‘core’’ TFs
that yield induced pluripotent stem (iPS) cells or direct lineage
conversion (Hanna et al., 2010; Morris and Daley, 2013; Orkin
and Hochedlinger, 2011; Takahashi and Yamanaka, 2006; Vier-
buchen and Wernig, 2011). These TFs bind and activate cis-
regulatory elements that modulate transcription and thereby
direct cell-type-specific gene expression programs (Lee and
Young, 2013).
Increasing evidence suggests that certain malignant tumors
also depend on a cellular hierarchy, with privileged sub-
populations driving tumor propagation and growth. Moreover,
many TFs that direct developmental decisions can also func-
tion as oncogenes by promoting the reacquisition of develop-
mental programs required for tumorigenesis (Suva` et al.,
2013). For example, the pluripotency and neurodevelopmental
factor SOX2 is an essential driver of stem-like populations in
multiple malignancies. Studies of leukemia pioneered the
concept that triggering cellular differentiation can abolish
certain malignant programs and override genetic alterations
(Ito et al., 2008; Wang and Dick, 2005). Similarly, iPS reprog-
ramming experiments have shown that artificially changing
cancer cell identity profoundly alters their properties (Stricker
et al., 2013). These findings suggest that epigenetic circuits
superimposed upon genetic mutations determine key features
of cancer cells.
The extent to which unidirectional differentiation hierarchies
underlie tumor heterogeneity remains controversial (Visvader
and Lindeman, 2012). For example, recent studies indicate that
stem-like cells in breast cancer and melanoma exist in dynamic
equilibrium with phenotypically distinct populations incapable
of tumor propagation (Chaffer et al., 2013; Roesch et al., 2010).
Alternatively, there is evidence supporting more classical
hierarchies in other cancers, particularly in leukemias (Wang
and Dick, 2005). In glioblastoma (GBM) models, reversibility
seems to depend on the differentiation stimulus and time of
exposure. Short-term exposure of GBM stem-like cells to
BMP4 is sufficient to abolish their tumor-propagating poten-
tial, which is consistent with unidirectional differentiation (Picci-
rillo et al., 2006). Serum-triggered differentiation appears to
proceed more gradually; short-term exposure can be reversed
(Lee et al., 2006; Natsume et al., 2013), whereas longer-term
exposure fully abolishes tumor-propagating potential (Janiszew-
ska et al., 2012; Lee et al., 2006; Wakimoto et al., 2009). A
better understanding of the molecular underpinnings that dis-
tinguish stem-like cancer cells and control plasticity within tu-
mors is a critical goal with broad implications for diagnosis and
therapy.
GBM is the most common malignant brain tumor in adults
and remains incurable despite aggressive treatment (Jansen
et al., 2010). Genome sequencing and transcriptional profiling
studies have highlighted a large number of genetic events and
identified multiple biologically relevant GBM subtypes, repre-
senting a major challenge for targeted therapy (Sturm et al.,
2012; Verhaak et al., 2010). There is strong evidence that
differentiation status significantly impacts GBM cell properties,
with stem-like cells likely driving tumor propagation and thera-
peutic resistance (Bao et al., 2006; Chen et al., 2012). Although
putative stem-like populations in GBM can be enriched using
cell surface markers such as CD133 (Singh et al., 2004),
SSEA-1 (Son et al., 2009), CD44 (Anido et al., 2010), and integrin
a 6 (Lathia et al., 2010), the consistency of the various markers
and the extent to which genetic heterogeneity contributes to
observed phenotypic differences remain controversial. A TF
code for GBM stem-like cells, analogous to those identified in
iPS reprogramming and direct lineage conversion experiments,
could thus provide critical insights into the epigenetic circuitry
underlying GBM pathogenesis.
Here, we combine functional genomics and cellular
reprogramming to reconstruct the transcriptional circuitry that
governs a developmental hierarchy in human GBM. By com-
paring the epigenetic landscapes of stem-like GBM cells
against their differentiated counterparts, we identify four core
TFs—POU3F2 (BRN2), SOX2, SALL2, and OLIG2—whose in-
duction is sufficient to reprogram differentiated GBM into
stem-like cells capable of in vivo tumor propagation. We use
this TF code to identify candidate tumor propagating cells
(TPCs) in primary GBM tumors. Genome-wide binding maps
and transcriptional profiles identify key regulatory targets of
the core TFs, including the RCOR2/LSD1 histone demethylase
complex. RCOR2 can substitute for OLIG2 in the reprogramming
cocktail, and, moreover, stem-like GBM cells are highly sensitive
to LSD1 suppression, thus validating the regulatory model. Our
findings demonstrate a cellular hierarchy in GBM, provide
detailed insight into its transcriptional and epigenetic basis,
and propose therapeutic strategies for eliminating stem-like
TPCs in human GBM.RESULTS
TF Activity and cis-Regulatory Elements Distinguish
GBM TPCs
To identify distinguishing features of stem-like GBM cells, we
expanded matched pairs of GBM cultures derived from three
different human tumors either as stem-like tumor-propagating
cells (TPCs) grown in serum-free, spherogenic culture, or as
differentiated glioblastoma cells (DGCs) grown as adherent
monolayers in serum. The alternate culture conditions confer
GBM cells with distinct functional properties, the key of which
is their in vivo tumor-propagating potential in orthotopic xeno-
transplantation limiting dilution assays (Figure 1A and Figure S1
available online) (Chudnovsky et al., 2014; Janiszewska et al.,
2012; Lee et al., 2006). This functional difference is accompanied
by differences in expression of stem cell (CD133 and SSEA-1),
astroglial (GFAP), neuronal (b III tubulin and MAP-2) and oligo-
dendroglial (GALC) markers (Figures 1B, 1C, and S1), which is
consistent with a modulation of the stemness-differentiation
axis by serum. Orthotopic xenotransplantation of as few as 50
GBM TPCs leads to formation of tumors that recapitulate major
histologic features of GBM (Figure 1D), whereas as many as
100,000 DGCs fail to initiate tumor. Importantly, although the
stem-like TPCs are able to differentiate and expand as mono-
layers when exposed to serum, DGCs will not expand in
serum-free conditions, suggesting that the differentiated state
is epigenetically stable. These functional and phenotypic proper-
ties suggest that a transcriptional hierarchy predicated on
distinct epigenetic circuits may be critical for the tumor-propa-
gating potential of GBM cells.
To acquire an epigenetic fingerprint of the respective GBM
models, we surveyed cis-regulatory elements in three matched
pairs of TPCs and DGCs established from three human tumors
(Experimental Procedures). We specifically mapped histone
H3 lysine 27 acetylation (H3K27ac), which marks promoters
and enhancers that are ‘‘active’’ in a given cell state (Bulger
and Groudine, 2011; Creyghton et al., 2010; Ernst et al.,
2011; Hon et al., 2009; Rada-Iglesias et al., 2011; Visel et al.,
2009) (Table S1). Unsupervised clustering indicates that the
TPCs share similar regulatory element patterning but are
distinct from the DGCs, which are also consistent across the
patient-derived samples (Figure S1). This suggests that regu-
latory element activity in our model correlates more closely
with phenotypic state than patient- or tumor-specific genetic
background.
To identify TFs that might direct these alternative cell states,
we collated sets of TPC-specific, DGC-specific, and shared
regulatory elements and searched the underlying DNA se-
quences for overrepresented motifs. TPC-specific elements
are strongly enriched for motifs recognized by helix-loop-helix
(HLH) and Sry-related HMG box (SOX) family TFs (Figure 1E),
whereas DGC-specific elements are instead enriched for AP1/
JUN motifs, which is consistent with a serum-induced differenti-
ation program (Zhu et al., 2013). We complemented these motif
inferences with RNA sequencing (RNA-seq) expression data
and promoter H3K27ac signals for TF genes to identify candi-
date regulators of the TPC state. This analysis yielded a set
of 19 TFs with significantly higher expression in TPCsCell 157, 580–594, April 24, 2014 ª2014 Elsevier Inc. 581
A B C
D E
P
E
FI
TC
P
E
FI
TC
D
G
C
-s
pe
ci
fic
Figure 1. Epigenetic Landscapes Distinguish Functionally Distinct GBM Models
(A) Survival curves for xenotransplanted mice. GBM cells (MGG8) grown as gliomaspheres in serum-free conditions propagate tumor in vivo, whereas serum-
differentiated cells fail to do so.
(B) Flow cytometry of MGG8 TPCs shows positivity for the GBM stem-like markers SSEA-1 and CD133, whereas serum-differentiated cells do not.
(C) Cells grow in serum as adherent monolayers and express the differentiation markers GFAP (astroglial), b III tubulin (neuronal), MAP-2 (neuronal), and GALC
(oligodendroglial).
(D) Xenografted tumors fromMGG8 TPCs (left) are invasive, crossing the corpus callosum (boxed region) and infiltrating along whitematter tracks (arrowhead). At
high magnification, the cells are atypical, and mitotic figures are evident (arrow). Xenografted tumors from MGG4 TPCs (right) are more circumscribed but also
infiltrate adjacent parenchyma (boxed region, arrowhead). At high-magnification areas of necrosis (*) and mitotic figures (arrow) are readily identified. LV, lateral
ventricle.
(legend continued on next page)
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Figure 2. Candidate Regulators for the Specification of Alternate Epigenetic States in GBM
(A) A set of 19 TPC-specific TFs is identified based on RNA-seq expression (red, high; blue, low) and promoter H3K27ac signals (green, high) in TPCs and DGCs
(TSS, transcriptional start site). TF family is indicated at right.
(B) Western blots confirm exclusive protein expression in TPCs for selected TFs. Bottom indicates tubulin loading control.
(C and D) (C) ChIP-seq tracks show H3K27ac signals for loci encoding TPC-specific TFs OLIG1, OLIG2, and SOX2 or (D) the differentiation factor BMP4 in the
respective GBM models. TPC-specific TF loci are enriched for TPC-specific regulatory elements.(Figures 2A–2C). Although we previously identified a set of 90
TFs active in GBM stem-like cells (Rheinbay et al., 2013), this
more restrictive set is limited to TFs that are specifically active
in TPCs and thus candidates for directing their epigenetic state.
Notably, 10 of the 19 TFs are HLH or SOX familymembers whose
cognate motifs were identified in our unbiased analysis of TPC-
specific regulatory elements.
Derivation of a Core TF Set Sufficient to Induce a TPC
Phenotype
Among the 19 TPC-specific TFs, SOX2, OLIG2, and ASCL1 have
been shown to be necessary for spherogenicity and tumor-prop-
agating potential of stem-like GBM cells (Gangemi et al., 2009;
Mehta et al., 2011; Rheinbay et al., 2013). However, the hypoth-
esized GBM developmental hierarchy raises the possibility that
certain combinations of TFs might be sufficient to reprogram
DGCs into TPCs, thus overriding an epigenetic state transition
that is irreversible in our model. Notably, several TPC-specific
TFs are components of cocktails that have been used to convert
fibroblasts into neurons (Pang et al., 2011) or neural stem cells(E) Heatmap depicts genomic intervals (rows) enriched for H3K27ac in tumormode
shared regulatory elements. Shared elements tend to be located proximal to prom
Motif analyses predict binding sites for TF families within each set of elements.
See also Figure S1.(Lujan et al., 2012). We therefore considered whether these prin-
ciples of cellular reprogramming could be applied to interconvert
epigenetic states in GBM.
To test the capacity of individual TFs or TF combinations to
reprogram GBM cells, we cloned all 19 TPC-specific TFs and
ectopically expressed them in DGCs. We then monitored
single-cell sphere formation in serum-free conditions, surface
marker induction, and tumor propagation by orthotopic
xenotransplantation into severe combined immunodeficient
(SCID) mice. We first introduced each TF individually. Of the 19
TFs, only SOX1, SOX2, andPOU3F2modestly enhanced sphero-
genesis, with POU3F2 in particular yielding 3% sphere forma-
tion (compared to 0% for empty vector and >10% for native
TPCs; Figure 3A). These TFs also stimulated weak induction of
thestemcellmarkerCD133 (Figure 3B).However, orthotopic xen-
otransplantation of as many of 100,000 DGCs expressing SOX1,
SOX2, or POU3F2 failed to initiate tumors in mice (Table S2).
Reasoning that successful GBM reprogrammingmight require
multiple TFs, we next coinfected DGCs with POU3F2 in combi-
nation with each of the other 18 TPC-specific TFs. We foundls (cyan: high signal), clustered into groups of TPC-specific, DGC-specific, and
oters, whereas the vast majority of TPC- and DGC-specific elements are distal.
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Figure 3. A Core TF Network for Tumor-Propagating GBM Cells
(A) Data points indicate percentage of single-cell DGCs capable of forming spheres in serum-free conditions. Each of the 19 TFs in Figure 2A was tested alone
(first column, ‘‘single TF’’) in combinationwith POU3F2 (second column) or in combination with POU3F2 and SOX2 (third column). HLH family TFswere also tested
in combination with POU3F2, SOX2, and SALL2 (fourth column) based on an enrichment of HLH motifs in regulatory elements that failed to activate in 3TF-
induced DGCs. TF combinations that enhanced in vitro spherogenicity (blue) were selected for in vivo testing. Error bars represent SEM in duplicate experiments.
(B) Flow cytometry profiles show expression of the stem cell marker CD133 for DGCs induced by the single, double, triple, and quadruple TF combinations with
the highest in vitro sphere-forming potential.
(C) For TF combinations with in vitro spherogenic potential (blue in A), 100,000 cells were injected in the brain parenchyma (n = 4 mice per TF combination).
Survival curve is shown for this in vivo tumor-propagation assay. Only the quadruple TF combination POU3F2+SOX2+SALL2+OLIG2 initiated tumors in mice.
(legend continued on next page)
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that coinfection of POU3F2 with SOX1 or SOX2 significantly
increased in vitro sphere-forming potential and CD133 expres-
sion (Figures 3A and 3B). However, neither 2TF combination
nor the SOX1+SOX2 combination initiated tumors in vivo (Table
S2). We thus resumed stepwise reconstruction experiments by
adding a third TF to the most effective pair (POU3F2+SOX2).
Although the addition of SALL2, SOX1, HEY2, or OLIG2
improved our in vitro results, none of these 3TF combinations
were sufficient to initiate tumors in vivo (Figures 3A–3C).
Failure to achieve complete reprogramming with these TF
combinations led us to consider whether TF induction effectively
activates TPC-specific regulatory elements, as would be ex-
pected in a successful reprogramming experiment. To test
this, we mapped H3K27ac-marked regulatory elements in
DGCs infectedwith POU3F2 alone, with the top 2TF combination
(POU3F2+SOX2), or with the top 3TF combination (POU3F2+
SOX2+SALL2). Each population gained TPC-specific elements
and lost DGC-specific elements, with the 3TF combination
inducing the most prevalent changes (Figure S2). Yet, despite
their spherogenic potential and CD133 expression, DGCs ex-
pressing the 3TF combination failed to induce a large number
of TPC-specific elements. Examination of the subset of TPC-
specific regulatory elements that remain silent in these partially
reprogrammed cells revealed a strong enrichment for HLH mo-
tifs (Figure S2), suggesting that complete reprogramming might
require an additional HLH TF.
We therefore supplemented the 3TF combination (POU3F2+
SOX2+SALL2) with each HLH factor in the TPC-specific TF
set, namely OLIG1, OLIG2, HEY2, HES6, and ASCL1. Although
none of these additions significantly enhanced in vitro assay
performance, combined induction of POU3F2+SOX2+SALL2+
OLIG2 yielded cells capable of tumor initiation in 100% of ani-
mals (Figures 3A–3C). This 4TF cocktail appears highly specific,
as four TF combinations with any of the other HLH factors failed
to initiate tumors. Moreover, replacement of SOX2 with SOX1 or
omission of any single component from the 4TF set yielded cells
without tumor initiating properties (Table S2).
Tumors initiated by ‘‘induced’’ TPCs (iTPCs) expressing the
four TFs show classical features of high-grade gliomas, including
necrosis, atypical cytonuclear features, and high mitotic index
(Figure 3D). Secondary sphere cultures derived from these
tumors express high levels of CD133 and display proliferation
and self-renewal properties in serial sphere formation assays,
similar to their corresponding TPC lines (Figures 3E–3G) (Barrett
et al., 2012; Chen et al., 2010). Similarly, serial xenotransplanta-
tion of these secondary cultures into SCID mice in limiting dilu-(D) Tumor histopathology shows characteristic features of glioblastoma, includ
magnification, cells show atypical features, and mitotic figures are evident (arrow
(E) Secondary TPC sphere cultures (iTPC) derived from xenotransplant tumors e
(F) Contrast field image of iTPC spheres.
(G) Left, bar graph shows iTPC and TPC proliferation rates measure by BrdU incor
sphere formation in three consecutive passages in serum-free conditions. Self-re
TPCs. Error bars indicate SEM based on two data points.
(H) Orthotopic serial xenotransplantation in limiting dilution shows that as few as
(I) Data points indicate in vitro sphere formation of MGG4 TPCs infected with lenti
(two hairpins per TF). Error bars represent SEM based on two data points.
(J) Survival curve depicts in vivo tumor-propagating potential of MGG4 TPCs inf
See also Figures S2, S3, and S4.tions indicates that as few as 50 iTPC cells initiate tumors in
50% of animals, whereas 500 cells confer tumor initiation in
100% of recipients (Figure 3H). Thus, we have identified a TF
cocktail sufficient to reprogram serum-derived differentiated
GBM cells into stem-like GBM cells capable of unlimited self-
renewal and tumor propagation.
To evaluate the generality of the TF cocktail, we tested its
ability to reprogram other DGC models. First, we confirmed
that the core TFs were capable of reprogramming a second
serum-derived DGC line from a different patient with different
genetic backgrounds (Figures 3G and 4A). Second, we tested
the effects of the TFs in an alternative differentiation model in
which TPCs are differentiated in serum-free conditions by
addition of BMP4 (Piccirillo et al., 2006). This treatment caused
the cells to adhere and downregulate the core TFs and CD133
over a 72 hr period. Reinduction of the core TFs in these differ-
entiated GBM cells re-established spherogenic potential and
CD133 expression over a 1 week period (Figure S3). These
data suggest that the core TF circuitry plays a general role in
modulating the GBM differentiation axis. Since the specific
GBM models investigated here conform to the proneural
subtype (Figure S1), further study will be needed to evaluate
the role of these TFs in other GBM subtypes (Verhaak et al.,
2010).
Core TFs Fully Reprogram the Epigenetic State of
Induced TPCs
To examine the extent to which the four core TFs reprogram
the epigenetic state of GBM cells, we surveyed regulatory
element activity and TF expression in secondary iTPC sphere
cultures. Consistent with their tumor-propagating ability, iTPCs
gain H3K27ac at most TPC-specific elements and lose
H3K27ac at the majority of DGC-specific elements (Figure 4A).
Furthermore, 18/19 TPC-specific TFs are upregulated in the
iTPCs, and most acquire H3K27ac at their promoter, indicating
that their epigenetic landscape closely resembles TPCs (Figures
4B and 4C). In contrast, DGCs expressing three TFs fail to reset
most TPC-specific and DGC-specific regulatory elements (Fig-
ure S2). Thus, all four core TFs are required to reprogram the
epigenetic landscape of GBM cells, which is consistent with their
requirement for the functional TPC phenotype.
We also considered the mechanistic basis for the sustained
phenotype of iTPCs. Several lines of evidence suggest that the
four core TFs are expressed from their endogenous loci in the
iTPCs, while the exogenously introduced expression vectors
are silenced. The endogenous TF genes contain 30 UTRs thating necrotic areas (*) and crossing of corpus callosum (boxed area). At high
s). LV, lateral ventricle.
xpress the stem-cell marker CD133.
poration. Right, data points indicate percentage of single cells capable of serial
newal properties and proliferation of iTPCs are comparable to corresponding
50 MGG8 iTPC are sufficient to initiate tumors.
virus containing shRNA for POU3F2,OLIG2, or SALL2, as compared to control
ected with POU3F2 shRNA, SALL2 shRNA, OLIG2 shRNA, or control shRNA.
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distinguish them from the exogenous versions, which lack UTRs.
RNA-seq profiles confirm endogenous transcripts with 30 UTRs
for POU3F2, SOX2, SALL2, and OLIG2 in iTPCs but reveal little
or no expression of the exogenous transcripts (Figure 4D). The
endogenous TF loci also gain H3K27ac at putative regulatory el-
ements, which is consistent with their reactivation (Figure 4E).
Finally, iTPCs markedly reduce expression of all four TFs and
readily differentiate upon exposure to serum (Figures 4F–4H),
as is indicative of endogenous regulation. These data suggest
that induction of the core TFs triggers an epigenetic state transi-
tion that is subsequently maintained by endogenous regulatory
programs.
Core TFs Coordinately Expressed in a Subset of GBM
Cells from Primary Human Tumors
To investigate the clinical relevance of our findings, we asked
whether the core TFs and corresponding regulatory elements
are active in primary human GBM tumors. First, we sought to
identify individual cells within GBM tumors that coexpress all
four core factors, postulating that these could represent candi-
date stem-like TPCs. We performed four-color immunofluores-
cence and five-color flow cytometry on freshly resected tumors
using antibodies against POU3F2, SOX2, SALL2, OLIG2, and
CD133. We found that SOX2 identifies the largest set of GBM
cells, whereas SALL2 and POU3F2 have more restricted expres-
sion. Image analysis and flow cytometry both identified a small
subset of cells in primary tumors (2%–7%) that coordinately
express all four TFs (Figures 5A and 5B). Remarkably, more
than 50%of the 4TF-positive cells also express CD133, a striking
enrichment over 4TF-negative cells, which almost entirely lack
this stem cell marker (Figure 5B). Finally, we also mapped
H3K27ac genome-wide in several freshly resected GBM tumors.
This bulk analysis revealed significant enrichment for 50% of
TPC-specific regulatory elements, suggesting that they are
also active in primary tumor cells (Figure 5C). Collectively, these
data suggest that the core TFs, regulatory elements, and circuits
defined in our TPC model are active in a subset of primary GBM
cells that express the stem cell marker CD133 and may underlie
tumor propagation.
Essential Roles for Core TFs and Their Regulatory
Targets in GBM TPCs
The identification of TPC-like cells in primary GBM tumors
prompted us to investigate the regulatory functions and inter-Figure 4. Core TFs Reprogram the Epigenetic Landscape of DGCs
(A) Left, heatmap depicts H3K27ac signals for TPC-specific, DGC-specific, or sha
DGCs, iTPCs gain H3K27ac over TPC-specific elements and lose H3K27ac over D
of the epigenetic landscape. Right, pie charts show fraction of regulatory elemen
(B) RNA-seq expression and promoter H3K27ac levels at promoter are shown fo
(C) Hierarchical clustering of MGG8 DGCs, TPCs, and replicate iTPCs (iTPC1/2)
(D) RNA-seq (30 end) tracks show that core TF mRNAs in iTPCs include 30 UTRs (s
the exogenous vectors lack 30 UTRs.
(E) H3K27ac signal tracks for loci encoding core TFs show that endogenous reg
(F andG) (F) Serum-induced differentiation leads iTPCs to convert to an adherent p
GALC and (G) to lose CD133 expression.
(H)Western blots confirm serum-induced differentiation of iTPCs leads to downreg
coreTFs can reprogramDGCs into stem-likeGBMcells,whichhaveanepigenetic l
See also Figure S2.actions of the core TFs, reasoning that this might suggest new
therapeutic targets or strategies. First, we confirmed that all
four TFs are essential for in vitro and in vivo TPC phenotypes.
Prior studies had established SOX2 and OLIG2 as essential reg-
ulators in this context (Gangemi et al., 2009; Mehta et al., 2011).
By performing shRNA-mediated knockdown in TPCs, we
showed that POU3F2 and SALL2 are also required for sphere
formation in vitro and for tumor propagation in vivo (Figures 3I,
3J, and S4).
To identify direct regulatory targets, we next mapped the
binding sites of POU3F2, SOX2, SALL2, and OLIG2 in TPCs
using chromatin immunoprecipitation sequencing (ChIP-seq)
with specific antibodies for each factor (Figures 6A and S5). All
four TFs preferentially associate with TPC-specific regulatory
elements, and there is significant overlap among their binding
sites (Figures 6B and S5). As expected, POU3F2, SOX2, and
OLIG2 binding sites are enriched for their cognate motifs. How-
ever, SALL2 sites are primarily enriched for SOX motifs (Fig-
ure 6C), raising the possibility that SALL2 is recruited as a
complex. Consistently, coimmunoprecipitation experiments
confirmed a direct interaction between SALL2 and SOX2
(Figure S5). Notably, single TF inductions in DGCs indicate that
POU3F2 and SOX2 are each capable of activating subsets
of TPC-specific elements. In contrast, neither OLIG2 nor
SALL2 is able to significantly alter the regulatory landscape of
DGCs in isolation (Figure S2). These results suggest that the
core TFs cooperatively engage TPC-specific regulatory ele-
ments to activate gene expression programs required for GBM
propagation.
To comprehensively identify functional targets of the core
TFs, we collated a list of genes within 50 kb of a bound regulatory
element and examined their expression by RNA-seq in TPCs
and DGCs. We identified 325 differentially expressed genes
with proximal H3K27ac-marked elements bound by one or
more core TFs. These putative direct targets include all
four core TF genes and 12 of the 19 TPC-specific TF genes (Fig-
ures 6D and 6E and Table S3), which is consistent with a role for
reciprocal TF interactions in maintaining the TPC regulatory
program.
Corepressor Subunit RCOR2 Can Replace OLIG2 in
Reprogramming Cocktail
We next focused on target genes of the core TFs that are active
in TPCs and iTPCs, but not in partially reprogrammed 3TFDGCs,red regulatory elements defined in Figure 1E. Relative to control vector infected
GC-specific elements, which is consistent with genome-wide reprogramming
ts (dark cyan) in each set with H3K27ac in iTPC.
r TPC-specific TFs defined in Figure 2A (NES, Nestin).
by H3K27ac ChIP-seq signal.
haded in gray). This indicates that endogenous loci are reactivated in iTPCs as
ulatory elements (highlighted with gray shading) are reactivated in iTPCs.
henotype, to upregulate differentiationmarkers GFAP, b III tubulin, MAP-2, and
ulation of core TFs. Bottom, tubulin loading control. These data indicate that the
andscape similar to TPCs that is sustainedbyendogenous regulatoryprograms.
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Figure 5. All Four Core TFs Are Coordinately Expressed in a Subset of Primary GBM Cells with Stem-like Markers
(A) Quadruple immunofluorescence for core TFs in three human GBM samples shows coexpression in a subset of cells; shown at right are the fractions of SOX2+
cells that express each other individual TF or all four TFs in each tumor. Error bars represent SD of positive cells across 10 fields examined.
(B) Flow cytometry analysis from acutely resected GBM tumors. Amajority of cells positive for the four core TFs express the stem-cell marker CD133. Enrichment
is significantly greater than for SOX2-expressing cells.
(C) Heatmap shows H3K27ac signal from three freshly resected GBM tumors for regulatory elements defined in Figure 1E. Right, pie charts show fraction of
regulatory elements (dark cyan) in each set with H3K27ac. TPC-specific elements show significant enrichment, which is consistent with a TPC-like regulatory
program in a subset of cells.
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Figure 6. TF Network Reconstruction and Targeting
(A) ChIP-seq signal for core TFs in TPCs (MGG8) is shown for regulatory element intervals defined in Figure 1E. Preferential binding is evident at TPC-specific
regulatory elements.
(B) Pie charts indicate proportion of TF binding sites that coincide with the indicated sets of regulatory elements.
(C) Sequence motifs identified in TF ChIP-seq peaks. With the exception of SALL2 (see Results and Figure S5), motifs correspond to the expected class of TFs,
further validating ChIP-seq experiments.
(D) Model for core TF regulatory interactions reconstructed from binding profiles and expression data (see Results and Experimental Procedures). Other TFs
defined in Figure 2A (green) and chromatin regulators (red) are highlighted.
(E) Signal tracks depict core TF binding over TPC-specific regulatory elements within loci containing the corresponding TF genes.
See also Figure S5.reasoning that these might represent critical nodes for the stem-
like GBMcells (see Experimental Procedures and Table S4). One
nuclear factor satisfying these criteria is the ASCL1 TF, which we
previously found to be an essential regulator of Wnt signaling inTPCs (Rheinbay et al., 2013). A second is RCOR2, a corepressor
with essential functions in embryonic stem cells (Yang et al.,
2011). RCOR2 resides in a complex with PHF21B and the his-
tone methyltransferase LSD1 (KDM1A), both of which wereCell 157, 580–594, April 24, 2014 ª2014 Elsevier Inc. 589
also identified as putative core TF targets (Shi et al., 2005; Yang
et al., 2011). LSD1, PHF21B, and RCOR2 are differentially ex-
pressed in TPC and DGC, with the latter undetectable at
mRNA and protein levels in DGCs (Figures 7A and 7B). We
also confirmed a robust physical interaction between RCOR2
and LSD1 in TPCs (Figure 7C).
Prior studies have suggested that RCOR2 is predominantly
expressed in embryonic stem cells, where it plays a role in
sustaining pluripotency. Although RCOR2 has not been impli-
cated in GBM, we hypothesized that it might play a key role in
initiation and maintenance of TPCs. Because RCOR2 is
downstream of OLIG2 in our network, we asked whether it could
substitute for OLIG2 in the reprogramming cocktail. We repeated
the DGC reprogramming and found that DGCs expressing
POU3F2, SOX2, SALL2, and RCOR2 could initiate tumor in
100% of cases, indicating that RCOR2 can replace OLIG2 and
establishing it as a key effector of the TPC regulatory program
(Figures 7D–7F).
Having established a critical role for RCOR2, we next asked
whether LSD1, an enzymatic subunit of the RCOR2 complex,
might also be essential. We performed shRNA knockdown of
LSD1 in TPCs and DGCs, confirming >80% reduction in LSD1
mRNA levels in both cases (Figure S3). Although the proliferation
and viability of DGCs were unaffected by the knockdown, the
TPC phenotype was profoundly altered, with marked reductions
in cell survival and near complete loss of self-renewal in serial
sphere formation assays (Figures 7G–7I). LSD1 knockdown
also caused TPCs to lose their capacity to initiate tumors in vivo
(Figure 7K). We also treated TPCs, DGCs, and normal human
astrocytes with increasing concentrations of the synthetic
LSD1 inhibitor S2101 (Mimasu et al., 2010). TPCs lose viability
in the presence of 20 mM inhibitor, whereas the DGCs and
astrocytes are unaffected (Figure 7J). These findings identify
the RCOR2/LSD1 histone demethylase complex as a candidate
therapeutic target in stem-like tumor propagating cells in
human GBM.
DISCUSSION
Hierarchies of cellular differentiation and the associated epi-
genetic mechanisms—long the domain of developmental
biology—are increasingly appreciated to play critical roles in
cancer. Pioneering work in leukemia led to the identification of
stem-like cells with high tumor-propagating potential that give
rise to differentiated progeny bearing identical genetic muta-
tions, knowledge that led to the successful application of differ-
entiation therapy (Ito et al., 2008; Wang and Dick, 2005). Recent
studies have established analogous hierarchies in certain solid
tumors, including glioblastoma, and thus point to the importance
of understanding the epigenetic identities and susceptibilities of
such aggressive subpopulations (Binda et al., 2012; Day et al.,
2013; Friedmann-Morvinski et al., 2012; Kim et al., 2013; Picci-
rillo et al., 2006; Singh et al., 2004; Son et al., 2009; Suva` et al.,
2013).
Here, we identified epigenetic determinants that distinguish
an established model of stem-like TPCs in GBM from their
differentiated progeny, which normally are unable to reacquire
stem-like properties. TFs, regulatory elements, and interactions590 Cell 157, 580–594, April 24, 2014 ª2014 Elsevier Inc.critical for the TPC state were predicted by integrating chro-
matin maps, RNA expression, and TF binding profiles. Four
core TFs were found to be sufficient to reprogram differentiated
GBM cells into iTPCs that faithfully recapitulate in vitro and
in vivo properties of TPCs established directly from human
tumors.
All four factors cobind large numbers of distal regulatory ele-
ments with specific activity in TPCs. SOX2 and POU3F2 can
each partially reprogram the epigenetic landscape of DGCs on
their own, which is consistent with their partial ability to induce
spherogenic growth and their established roles in direct conver-
sion to neural lineages (Lodato et al., 2013; Lujan et al., 2012;
Pang et al., 2011). Furthermore, SALL2 and SOX2 collaborate
through a direct physical interaction that has not been previously
described. The pervasive regulatory interactions of these neuro-
developmental factors and their efficacy in GBM reprogramming
suggest that the malignant hierarchy maintains key features of
normal developmental processes.
A limitation of our study is that in vitro TPC andDGCmodels do
not fully recapitulate the diversity of cellular states within primary
human GBMs. Nor does our work establish whether retrograde
dedifferentiation can actually occur in primary tumors. Nonethe-
less, the clinical relevance of our findings is supported by (1) the
identification of stem-like cells that coordinately express all four
factors in primary GBM tumors, (2) confirmation that large
numbers of TPC-specific regulatory elements are active in pri-
mary tumors, and (3) the requirement of all four factors for in vivo
tumorigenicity in xenotransplanted mice. Given their demon-
strated functionality, the core TFs may have specific advantages
for enriching aggressive cellular subsets relative to conventional
surface markers that have been defined empirically and remain
controversial. This may be most apt in IDH1 wild-type proneural
tumors, which account for roughly a quarter of humanGBMs and
are best represented by our cellular models.
In considering therapeutic opportunities presented by the
TPC regulatory program, we focused on potential targets down-
stream of the core TF network. We identified the RCOR2-LSD1
complex as a key effector of the TPC regulatory program.
RCOR2 can substitute for OLIG2 in the reprogramming cocktail,
whereas LSD1 suppression triggered cell death exclusively in
TPCs. This vulnerability is consistent with an established require-
ment for LSD1 in leukemia stem cells and in SOX2-expressing
cancer cell lines (Harris et al., 2012; Zhang et al., 2013). Thus,
dissection of the epigenetic circuitry governing a malignant
hierarchy may guide therapeutic strategies for targeting cancer
stem cells.
In conclusion, we have elucidated epigenetic fingerprints of
key subpopulations within the cellular hierarchy of GBM, identi-
fied core TFs that direct the hierarchy and control tumor-propa-
gating potential, and established a histone demethylase complex
as a candidate therapeutic target in stem-like tumor cells.
Although the specific tumor model characterized here conforms
to a unidirectional hierarchy, our reprogramming experiment
suggests a mechanism by which bidirectional plasticity may
occur in certain clinical contexts. Further studies will be needed
to assess translational opportunities in GBM and to evaluate
the relative merits of hierarchical and plasticity-based cellular
models across the diverse spectrum of human malignancies.
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Figure 7. The LSD1-RCOR2 Chromatin Complex Is Essential for GBM TPCs
(A) Plots depict LSD1 and RCOR2 RNA-seq expression values for TPCs and DGCs. Error bars indicate SEM based on three data points.
(B) Western blot for RCOR2 (MGG8 TPC and DGC lysates) confirms exclusive expression in TPC.
(C) Western blot for LSD1 on RCOR2 immunoprecipitate indicates coassociation between the two proteins in TPCs.
(D) Signal tracks depict TF binding and H3K27ac enrichment in the RCOR2 locus. OLIG2 binds a TPC-specific regulatory element in the locus.
(E) Survival curve of mice injected with DGCs induced with the combination of POU3F2+SOX2+SALL2+RCOR2 indicates that RCOR2 can substitute for OLIG2 in
the cocktail.
(F) Coronal section of a xenografted GBM tumor (dashed line) established from iTPCs reprogrammed with the POU3F2+SOX2+SALL2+RCOR2 combination.
(G) Representative images of TPCs and DGCs infected with LSD1 shRNA show reduced viability specifically in the TPCs.
(H) Bar graphs depict percent viability for MGG4 TPCs or DGCs infected with control shRNA or two different LSD1 shRNAs. LSD1 depletion causes decreased
viability in TPCs but has no effect on DGCs. Error bars represent SEM in duplicate experiments.
(I) Data points indicate in vitro sphere formation of MGG4 TPCs infected with lentivirus shRNA for LSD1 (two hairpins), compared to control in three serial
passages. Error bars indicate SEM based on two data points.
(J) Graph depicts percent viability for TPCs and DGCs (MGG4 and MGG8) and primary astrocytes (NHA) exposed to increasing doses of the synthetic LSD1
inhibitor S2101. A representative image of TPCs exposed to 20 mM S2101 for 96 hr is shown below. Error bars indicate SEM in duplicate experiments.
(K) Survival curve depicts in vivo tumor-propagating potential of MGG4 TPCs infected with LSD1 shRNA (two hairpins) or control shRNA. These data suggest that
the RCOR2/LSD1 complex is essential for stem-like TPCs and thus represents a candidate therapeutic target for eliminating this aggressive GBM subpopulation.
See also Figure S4.
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EXPERIMENTAL PROCEDURES
Cell Culture
Surgically removed GBM specimens were collected at Massachusetts Gen-
eral Hospital with approval by the Institutional Review Board (IRB protocol
2005-P-001609/16). Tissue was processed as previously described (Rheinbay
et al., 2013). See also Extended Experimental Procedures.
Flow Cytometry and Immunofluorescence
CD133/1-PE or CD133/2-APC (Miltenyi Biotec) and SSEA-1-FITC (BD Biosci-
ences) antibodies were used according to manufacturer’s instructions. For TF
staining in primary tumors, single-cell suspensions were depleted for CD45-
positive cells using a MACS separator (Miltenyi Biotec). Antibodies to
SOX2 (R&D Systems), POU3F2 (Bethyl), SALL2 (Bethyl), and OLIG2 (R&D
Systems) were directly conjugated to fluorophores using Alexa Fluor Conjuga-
tion Kits (Invitrogen) or DyLight conjugation kits (Pierce). The CD45-negative
fraction was stained with CD133-PE or CD133-APC prior to fixation and per-
meabilization according to manufacturer’s protocol using the Transcription
Factor Buffer Set (BD PharMingen). Single-color controls for all fluorophores
were used for compensation. Flow cytometric analysis was conducted with
an LSR II flow cytometer (BD Biosciences), and analysis was performed with
FlowJo software (Treestar). See also Extended Experimental Procedures.
ChIP-Seq Assay and 30 End RNA-Seq
ChIP-seq assays were carried out on 1 3 106 cells per histone modification
and107 cells per transcription factor, following the procedures outlined in Ku
et al. (2008) and Mikkelsen et al. (2007). For primary GBM, cells were dissoci-
ated into single-cell suspension, followed by depletion for CD45+ inflamma-
tory infiltrate as outlined in previous methods. Immunoprecipitation was
performed using antibodies against H3K27ac (Active Motif), POU3F2 (Epi-
tomics), SOX2 (R&D), SALL2 (Bethyl), and OLIG2 (R&D). ChIP DNA samples
were made into libraries for sequencing on the Illumina HiSeq 2000 or 2500
following standard procedures. See Extended Experimental Procedures for
ChIP-seq data processing and regulatory network reconstruction. ChIP-seq
data are available for viewing at http://www.broadinstitute.org/epigenomics/
dataportal/clonePortals/Suva_Cell_2014.html. For 30 end RNA-seq, total
RNA was isolated from cells using the RNeasy Kit (QIAGEN). We used 2 mg
of total RNA to fragment and polyA isolate the 30 ends of mRNAs. Illumina
sequencing libraries were constructed and subjected to high-throughput
sequencing. A processing pipeline incorporating Scripture (http://www.
broadinstitute.org/software/scripture/) was used to reconstruct the transcrip-
tome and calculate gene expression values as previously described (Menden-
hall et al., 2013; Yoon and Brem, 2010). Data accompanying this paper are
available through GEO under GSE54792. See also Extended Experimental
Procedures.
Generation of H3K27ac Consensus Sets
H3K27ac sites shared between 4, 6, and 8 TPCs and corresponding DGCs
were defined as those that were present in each of the six ChIP-seq experi-
ments. TPC-specific sites were required to be present in all three TPC lines
and not in any of the DGC lines, and accordingly, DGC-specific sites were
required to be present in all DGC lines, but not in any of the TPC lines. For heat-
maps, H3K27ac or TF signal in a 10 kb region for each site was obtained. Total
signal was thresholded at the 95th (H3K27ac) or 99th (TFs) percentile and
scaled to values between 0 and 1. See also Extended Experimental Proce-
dures for H3K27ac-based cell-type clustering.
Generation of TF List for Experimental Testing and Motif Analyses
TFs from the ‘‘CSC’’ and ‘‘stem-cell’’ sets from Rheinbay et al. (2013) were
included in the testing set. TFs were then filtered for fold difference between
TPCs and DGC, and only those at least 1.5-fold overexpressed in TPC relative
to DGC were kept for further analysis. See also Extended Experimental
Procedures.
Knockdown and Overexpression Experiments
For knockdown experiments, the following lentiviral shRNA sets from
Thermoscientific were used: POU3F2 (RMM4532-NM_005604), OLIG2592 Cell 157, 580–594, April 24, 2014 ª2014 Elsevier Inc.(RHS4531-NM_005806), SALL2 (RHS4531-NM_005407), and LSD1
(RHS4531-EG23028). Lentiviruses were produced as previously described
(Rheinbay et al., 2013). GBM TPCs were selected using 2 mg/ml puromycin
for 5 days. GBM non-TPCs were selected using 1 mg/ml puromycin for
5 days. After selection, RNA was extracted (QIAGEN RNeasy kit) following
manufacturer’s instructions. See also Extended Experimental Procedures.
Single-Cell Sphere-Formation Assay and BrdU
For each condition (shRNA of TFs in GBM TPC or cDNA overexpression in
DGC), single cells were plated in 150 ml of serum-free medium in a 96 well
plate. Sphere number/96 well plate was assessed after 2 weeks. The mean
and SD of two biological replicates were calculated. In serial sphere-forming
assays, the same procedure was repeated for two additional passages.
BrdU assays were performed following manufacturer’s recommendations
(Roche).
Chemical Inhibition of LSD1
TPCs, DGCs, and normal human astrocytes were plated 24 hr prior to addition
of the LSD1 inhibitor S2101 (Millipore/Calbiochem). The untreated controls
for each cell type received DMSO as vehicle. Dilution series ranged from
0–100 mM.Media and inhibitor were refreshed every 96 hr for a 14 day duration.
Percent viability was determined by Trypan blue staining.
Tumorigenicity Study
Intracranial injections were performed with a stereotactic apparatus (Kopf
Instruments) at coordinates 2.2 mm lateral relative to Bregma point and
2.5 mm deep from dura mater. Four SCID mice (NCI Frederick) were used
per condition. For cDNA overexpression experiments, 100,000 cells were
used per mouse, unless otherwise specified. For shRNA experiments, 5,000
TPC cells per mouse were injected. Kaplan-Meier curves and statistical signif-
icance (log rank test) were calculated with the R survival package (R, 2008).
Animal experiments were approved by the Institutional Animals Care and
Use Committee (IACUC) at Massachusetts General Hospital.
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